Overview
Mantis Biotech has raised $6.3M in a Seed round on Jan 29, 2026, with participation from Decibel Partners. The company the data platform for life sciences performance. The round will be used to accelerate product development, expand the team, and scale go-to-market operations.
Operating in the biotechnology research sector, Mantis Biotech is positioned to capitalize on growing demand for innovative solutions in this space. With fresh capital, the company is expected to invest heavily in R&D and talent acquisition, signaling a period of aggressive growth ahead.
Market Outlook
The successful raise validates Mantis Biotech's approach and market opportunity. Industry analysts note that companies at this funding stage typically grow headcount by 40-60% within 12 months and make significant technology purchasing decisions in the first quarter post-funding. This makes Mantis Biotech's leadership team particularly valuable contacts for B2B outreach in the near term.
Why contact Mantis Biotech now
Mantis Biotech's $6.3M Seed raise signals serious investor confidence in their biotechnology research play. In the first 90 days post-funding, startups are 3x more likely to respond to outreach and evaluate new partnerships. Their team is hiring, their budget is unlocked, and they need solutions yesterday.
Founders & Contacts
Investors
Company Facts
| Company | Mantis Biotech |
| Amount Raised | $6.3M |
| Funding Round | Seed |
| Date Raised | Jan 29, 2026 |
| Founded | 2025 |
| Industry | Biotechnology Research |
| Founders |
Get Verified Founder Emails
Access verified email addresses and contact details for Mantis Biotech's founders and thousands of other funded startups.
Start Free Trial